Právní předpis byl sestaven k datu 07.04.2026.
Zobrazené znění právního předpisu je účinné od 28.01.2025.
19
XXXXXXX
Xxxxxxxxxxxx zahraničních xxxx,
xxxxxx xx mění x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
&xxxx;
Xxxxxxxxxxxx zahraničních xxxx xxxxxxx, xx xxx 1. xxxxx 2023 bylo generální xxxxxxxxxx UNESCO xxxxxxxx xxxxxxxxx xxxxxx znění Xxxxxxx X - Xxxxxx zakázaných xxxxx x xxxxx dopingu xxx rok 2024 - Mezinárodní xxxxxxxx Xxxxxxxxxxx úmluvy proti xxxxxxx ve xxxxxx.
X xxxxx zněním Přílohy X vyslovil souhlas Xxxxxxxxx České republiky x prezident xxxxxxxxx xxxxxxxx xxxxxxx o xxxxxxx xxxx Přílohy X Xxxxxx republikou.
Nové xxxxx Přílohy X xxxxxxxxx x xxxxxxxx x souladu x článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2024, xxx Xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx xxx 18. xxxxxx 2024 x xxxxxxxxx Xxxxxxx X pro xxx 2023, xxxxxxx xx 1. xxxxx 2023, xxxxx vstoupila x xxxxxxxx xxx Českou xxxxxxxxx xxx 22. xxxxxx 2023 a xxxx vyhlášena pod č. 32/2023 Sb. m. s.
Xxxxxxxx znění Přílohy X xxx rok 2024 a její xxxxxxx do xxxxxxx xxxxxx xx vyhlašují xxxxxxxx.
&xxxx;
Xxxxxxx:
x z. JUDr. Xxxxxx, Xx.X., LL.M., x. r.
vrchní xxxxxxx xxxxx právní x xxxxxxxxxx
&xxxx;
Xxxxxxx x. 1
Xxxxxxx xxxxxxxxxxx xxxxxxx do xxxxxxx xxxxxx
Xxxx
Xxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx je povinný Xxxxxxxxxxx xxxxxxxx x xxxxx Xxxxxxxxx antidopingového xxxxxxxx.
Xxxxxx xx xxxxxxxxxx xxxxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx procesu zprostředkovaném Xxxxxxxx antidopingovou xxxxxxxxx (XXXX). Seznam je xxxxxx xx 1. xxxxx 2024.
Xxxxxxxxx text Xxxxxxx zakázaných látek x xxxxx xxxx xxxxxxxxx WADA x xxxx xxxxxxxxxx v xxxxxxxxxx x francouzštině. X případě jakýchkoliv xxxxxxxxxxxxx xxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxx xxxxxxxxx znění v xxxxxxxxxx.
Xxxx xxxx xxxxxxx xxxxxxx xxxxx používané x xxxxx Xxxxxxx xxxxxxxxxx xxxxx x xxxxx.
Xxxxxxxx Xxx xxxxxxx
Xxxxx XXXX xxx xxxx xxxxx xxxxxxxxxxx xxxx xxxxxx, je xxxxxx Xxx xxxxxxx v xxxxxx xxxxxxx xxxxxxxxxxx xxxxx před xxxxxxx (xx 23:59 hodin) x xxx xxxxxxxxxxxxx Xxxxxxx, xxxxx se xx Sportovec zúčastnit, xx xx konce Xxxxxxx a xxxxxxx xxxxxx Xxxxxx.
Xxxxxxxx stále
To xxxxxxx, že xxxx xxxxx xxxx xxxxxx xx xxxxxxxx Xxx xxxxxxx x Mimo xxxxxx, xxx xx xxxxxxxxxx v Xxxxxx.
Xxxxxxxxxx x Xxxxxxxxxxxx
Xxxxx xxxxxx 4.2.2 Světového antidopingového Xxxxxx „xxx účely xxxxxxxx xxxxxx 10 xxxxx xxxxxxx Xxxxxxxx xxxxx Xxxxxxxxxxxx xxxxxxx, x xxxxxxxx těch xxxxxxxxxx x Xxxxxxx xxxxxxxxxx látek x xxxxx xxxxxxx. Xxxxx Xxxxxxxx metoda xxxxxx Xxxxxxxxxxx xxxxxxx, xxxxx xxxx x Seznamu xxxxxxxxx označena xxxx Xxxxxxxxxx xxxxxx.“ Xxxxx xxxxxxxxx x článku „Xxxxxxxxxx látky x Xxxxxxxxxx metody xxxxxxx x xxxxxx 4.2.2 xx neměly xxx xxxxxx xxxxxxxx xxxxxxxxxx xx méně xxxxxxxx xxxx xxxx xxxxxxxxxx xxx xxxx xxxxxxxxx xxxxx xxxx xxxxxx. Xxx xxxxx o xxxxx x metody, xxxxx Sportovec xxxxxxxxxxxxx xxxx xxxx xxxxxx x xxxxxx xxxxx xxx xx zlepšení xxxxxxxxxxx xxxxxx.“
Xxxxxxxx xxxxx
Xxxxx xxxxxx 4.2.3 Kodexu xxxx Xxxxxxxx xxxxx xxxxxxxxxx jako látky, xxxxx xxxx xxxx xxxxxx xxxxxxxx x xxxxxx jejich xxxxxxx xxxxxxxxxx xx xxxxxxxxxxx xxxx xxxxx xxxxxx. Xxxx Xxxxxxxx xxxxx xxxx označovány xxxx xxxxx: kokain, xxxxxxxxx (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (XXX).
X0 XXXXXXXXXXX XXXXX
XXXXXXXX STÁLE (PŘI XXXXXXX X XXXX XXXXXX)
Xxxxxxx zakázané látky x xxxx xxxxx xxxx Xxxxxxxxxx látky.
Jakákoliv xxxxxxxxxxxxxx látka, xx xxxxxx xx nevztahuje xxxxx z xxxxxxxxxxxxx xxxxxx Seznamu a xxxxx xxxx x xxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxx xxxxxxx xxxxxxx u xxxx (např. xxxxxx x předklinickém nebo xxxxxxxxx xxxxxx xxxx xxxxxxx vývoj xxx xxxxxxx, syntetické xxxxx, xxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxxxx), xx xxxxxxxx stále.
Tato xxxxx xxxxxxxx mnoho xxxxxxx xxxxx, xxxx xxxx XXX-157, 2,4-xxxxxxxxxxxx (XXX) x xxxxxxxxxx xxxxxxxxx (např. Xxxxxxxxxxx x Xxxxxxxxxx).
X1 XXXXXXXXXX XXXXX
XXXXXXXX STÁLE (PŘI XXXXXXX X XXXX XXXXXX)
Xxxxxxx zakázané látky x xxxx xxxxx xxxx Nespecifické xxxxx.
Xxxxxxxxxx xxxxx jsou zakázány.
S1.1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX)
Xxx xxxxxxxxx xxxxxx, xxxx jiné xxxxxx:
|
• |
1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3ß, 17ß-xxxx) |
&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx; |
&xxxx;•&xxxx; |
xxxxxxxxxx |
|
• |
1-xxxxxxxxxxxxxx (5ɑ-androst-1-en-3,17-dion) |
• |
furazabol (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx) |
|
|
• |
1-xxxxxxxxxxx (3ɑ-hydroxy-5a-androst-1-en-17-on) |
• |
gestrinon |
|
|
• |
1-epiandrosteron (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
1-xxxxxxxxxxx (17ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-3-xx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
4-xxxxxxxxxxxxxx (androst-4-en-3ß, 17ß-xxxx) |
&xxxx;• |
xxxxxxxxxxx (17ß-hydroxy-17ɑ-methylandrosta-1,4-dien-3-on) |
|
|
• |
4-hydroxytestosteron(4,17ß-dihydroxyandrost-4-en-3-on) |
• |
metenolon |
|
|
• |
5-androstenedion (xxxxxxx-5-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
7ɑ-xxxxxxx-XXXX |
&xxxx;• |
xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx) |
|
|
• |
7ß-xxxxxxx-XXXX |
&xxxx;• |
xxxxx-1-xxxxxxxxxxx (17ß-hydroxy-17ɑ-metyl-5ɑ-androst-1-en-3-on) |
|
|
• |
7-keto-DHEA |
• |
metylklostebol |
|
|
• |
11ß-metyl-19-nortestosteron |
• |
metyldienolon (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx) |
|
|
• |
17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx) |
&xxxx;• |
xxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxx-4-xx-3-xx) |
|
|
• |
19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxxxxxxxx |
|
|
• |
19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx (xxxxxxxxxxxxxx, 17ß-hydroxy-17ɑ-methylestra-4,9,11-trien-3-on) |
|
|
• |
Androst-4-en-3,11,17-trion(11-ketoandrostenedion, xxxxxxxxxxxx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxx (5ɑ-xxxxxxxxxxxxxxxxxx, 17ß-hydroxy-5ɑ-androstan-3-on) |
• |
nandrolon (19-xxxxxxxxxxxxxx) |
|
|
• |
xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxxxxxx (androst-4-en-3,17-dion) |
• |
norklostebol (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx) |
|
|
• |
xxxxxxxxxx |
&xxxx;• |
xxxxxxxxxxxxx |
|
|
• |
xxxxxxxx |
&xxxx;• |
xxxxxxxx |
|
|
• |
xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
&xxxx;• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxx |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxx ([1,2]oxazolo[4’,5’:2,3]pregna-4-en- 20-xx-17ɑ-xx) |
&xxxx;• |
xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA, 3β-xxxxxxxxxxxxxx-5-xx-17-xx) |
|
|
• |
xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxx-1,4-xxxx-3-xx) |
&xxxx;• |
xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx) |
|
|
• |
xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx a 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxxx (3β-hydroxy-5α-androstan-17-on) |
• |
testosteron |
|
|
• |
epi-dihydrotestosteron (17β-xxxxxxx-5β-xxxxxxxxx-3-xx) |
&xxxx;• |
xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxx |
|
|
• |
xxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx) |
&xxxx;• |
xxxxxxxxx (17β-hydroxyestr-4,9,11-trien-3-on) |
|
|
• |
fluoxymesteron |
• |
trestolon (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, MENT) |
a další xxxxx s xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
X1.2. XXXXXXX XXXXXXXXXX XXXXX
Xxxx xxxx xxxxxx:
Xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, selektivní modulátory xxxxxxxxxxxxx xxxxxxxxx [SARM, xxxx. xxxxxxx, xxxxxxxxx (xxxxxxx), LGD-4033 (xxxxxxxxx), XXX140, X-23 x XX-11], xxxxxxx a xxxxxxxxxx.
X2 PEPTIDOVÉ XXXXXXX, XXXXXXX XXXXXXX, PŘÍBUZNÉ XXXXX X XXXXXXXX
XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX)
Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxxxx xxxxx.
Xxxxxxxxxxx látky x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx účinky jsou xxxxxxxx.
X2.1. XXXXXXXXXXXXX (XXX) X LÁTKY XXXXXXXXXXX XXXXXXXXXXX
Xxxx xxxx xxxxxx:
X2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx. xxxxxxxxxxxx (xXXX); xxxxxxxxxxxxx (EPO); xxxxxxxxxx xxxxxxxx xx EPO, [xxxx. XXX-Xx, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)]; XXX- xxxxxxxxx xxxxxxxxxx x xxxxxx xxxxxxxxxx, xxxx. XXXX-530, xxxxxxxxxxx.
X2.1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxx; xxxxxxxxxxx (GSK1278863); XXX2; molidustat (XXX 85-3934); roxadustat (XX-4592); xxxxxxxxxx (XXX-6548); xxxxx.
X2.1.3 Xxxxxxxxxx XXXX, např. X-11706.
X2.1.4 Xxxxxxxxxx signalizace xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxx (XXX-β), xxxx. xxxxxxxxxxxx; xxxxxxxxxxx.
X2.1.5 Agonisté xxxxxxxxx xxxxxxxxx xxxxxxxxx, xxxx. asialo EPO; xxxxxxxxxxxxx XXX (XXXX).
X2.2. XXXXXXXXX XXXXXXX X XXXXXX XXXXXXXXXX FAKTORY
S2.2.1 Xxxxxxx xxxxxxxxxxx xxxxxxxxxxx x xxxx, mimo xxxx xxxxxx:
• xxxxxxxx xxxxxxxxxxxx (CG),
• xxxxxxxxxxxx xxxxxx (XX),
• xxxxxx xxxxxxxxxx xxxxxxxxxxxx (GnRH, xxxxxxxxxxx) x jeho xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxxxx, deslorelin, goserelin, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx x xxxxxxxxxxx),
&xxxx;• kisspeptin x jeho xxxxxxxxxxx xxxxxxx.
X2.2.2 Xxxxxxxxxxxxxx x xxxxxx xxxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxx x xxxxxxxxxxxxx.
X2.2.3 Xxxxxxx hormon (XX), xxxx analogy x xxxxxxxxx, xxxx xxxx xxxxxx:
• xxxxxxx xxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxx,
• xxxxxxxxx xxxxxxxxx xxxxxxx, xxxx. AOD-9604 x xXX 176–191.
X2.2.4 Xxxxxxx xxxxxxxxxx xxxxxxx xxxxxx, xxxx xxxx xxxxxx:
• xxxxxx uvolňující xxxxxxx hormon (XXXX) x xxxx xxxxxxx, xxxx. XXX-1293, XXX-1295, xxxxxxxxxx x xxxxxxxxxxx,
• xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX) x jejich xxxxxxxx [xxxx. anamorelin, xxxxxxxxxxxx, ibutamoren (XX-677), xxxxxxxxxx, xxxxxxxxxxx (ghrelin), xxxxxxxxxxx a xxxxxxxxxxx],
• xxxxxxx uvolňující XX (XXXX) [xxxx. xxxxxxxxxxxx, xxxxxxxxxx (hexarelin), GHRP-1, XXXX-2 (pralmorelin), XXXX-3, XXXX-4, XXXX-5 x XXXX-6].
X2.3. RŮSTOVÉ XXXXXXX X XXXXXXXXXX RŮSTOVÝCH XXXXXXX
Xxxx jiné včetně:
• xxxxxxxxxxxxx růstové faktory (XXX)
• hepatocytový růstový xxxxxx (XXX)
• růstový xxxxxx 1 podobný xxxxxxxx (XXX-1, xxxxxxxxxx) x xxxx xxxxxxx
• xxxxxxxxxx xxxxxxx xxxxxxx (XXX)
• xxxxxxx xxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX)
• xxxxxxxx-β4 x jeho xxxxxxxx, xxxx. TB-500
• xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX)
x xxxxx xxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx syntézu/degradaci xxxxxxxx xx svalech, xxxxxxxx xxxx xxxxxx, xxxxxxxxxxxxx, využití xxxxxxx, xxxxxxxxxxxxx kapacitu nebo xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.
X3 XXXX-2 XXXXXXXX
XXXXXXXX XXXXX (PŘI XXXXXXX X MIMO XXXXXX)
Xxxxxxx xxxxxxxx xxxxx v xxxx třídě jsou Xxxxxxxxxx xxxxx.
Xxxxxxx xxxxxxxxxx x xxxxxxxxxxxx beta-2 xxxxxxxx xxxxxx xxxxx xxxxxxxxx izomerů xxxx xxxxxxxx.
Xxxx jiné včetně:
|
• |
arformoterol |
• |
indakaterol |
• |
reproterol |
• |
tretoquinol (xxxxxxxxxxxxx) |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
XXXXXXX
• Xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 hodin x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 600 xxxxxxxxxx xxxxx 8 xxxxx xx xxxxxxxxx xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx xxxxxx xxxxx 54 xxxxxxxxxx xx 24 xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 hodin;
• xxxxxxxxx xxxxxxxxxx: maximálně 25 xxxxxxxxxx xx 24 hodin.
POZNÁMKA
Přítomnost xxxxxxxxxxx x xxxx x xxxxxxxx xxxxxx xxx 1000 xx/xx xxxx xxxxxxxxxxx x xxxxxxxx xxxxxx než 40 xx/xx neodpovídá terapeutickému xxxxxxx látky x xxxx považována xx Xxxxxxxxx xxxxxxxxxxx nález (XXX), xxxxx Sportovec xxxxxxxxx xxxxxxxxxxxxx farmakokinetickou xxxxxx, že xxxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxxxxxxx xxxxx (xxxxxxxxx) xx do xxxx xxxxxxx xxxxxxxxx dávky.
S4 XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX
XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX)
Xxxxxxxx xxxxx xx xxxxxxx X4.1 a X4.2 jsou Xxxxxxxxxx xxxxx.
Xxxxx zařazené do xxxx X4.3 x X4.4 xxxx Xxxxxxxxxxxx xxxxx.
Xxxxxxxxxxx hormonové a xxxxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.
X4.1. XXXXXXXXXX XXXXXXXX
Xxxx xxxx včetně:
|
• |
2-androstenol (5ɑ-androst-2-en-17-ol) |
• |
androsta-1,4,6-trien-3,17-dion (xxxxxxxxxxxxxxxxx) |
|
|
• |
2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx) |
• |
xxxxxxxx-3,5-xxxx-7,17-xxxx (arimistan) |
|
|
• |
3-androstenol (5ɑ-xxxxxxx-3-xx-17-xx) |
• |
xxxxxxxxx |
|
|
• |
3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx) |
• |
xxxxxxxxx |
|
|
• |
4-xxxxxxxxx-3,6,17 xxxxx (6-xxx) |
• |
xxxxxxxx |
|
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
X4.2. XXXXXXXXXXXXXX XXXXX [XXXXXXXXXXXXX X SELEKTIVNÍ XXXXXXXXXX XXXXXXXXXXXXX XXXXXXXXX (XXXXX)]
Xxxx jiné xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx (xxxxxxxxxxxxx) |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
X4.3. LÁTKY XXXXXXXXXXX XXXXXXXX XXXXXXXXX XXXXXXXX XXX
Xxxx jiné včetně:
|
• |
protilátky xxxxxxxxxxxxxx aktivin A |
• |
inhibitory xxxxxxxxxx, xxxx.: |
|
|
• |
xxxxxxxxxx receptoru xxxxxxxx XXX, xxxx.: |
- xxxxx snižující xxxx xxxxxx expresi xxxxxxxxxx |
||
|
- xxxxxxx receptory aktivinu (xxxx. ACE-031) |
- xxxxxxxx xxxxxx xxxxxxxxx (xxxx. xxxxxxxxxxx, xxxxxxxxx myostatinu) |
|||
|
• |
protilátky xxxxx xxxxxxxxx aktivinu XXX (xxxx. xxxxxxxxxx) |
- xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxx prekurzory (např. xxxxxxxxxxx, xxxxxxx xxxxx, xxxxxxxxxxxxx, xxxxxxxxxx) |
X4.4. XXXXXXXXXXX XXXXXXXXXX
X4.4.1 xxxxxxxxxx AMP-aktivované xxxxxxxxxxxxx (AMPK), např. XXXXX, agonisté xxxxxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx receptoru xxxxx (PPARδ), např. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (xxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxx)xxxxxx) kyselina xxxxxx (XX1516, GW501516) x xxxxxxxx Rev-erbɑ , xxxx. XX9009, XX9011
X4.4.2 xxxxxxxx x xxxxxxxx xxxxxxxx
X4.4.3 xxxxxxxxx
X4.4.4 xxxxxxxxxxxx
X5 DIURETIKA X XXXXXXXXX XXXXX
XXXXXXXX XXXXX (XXX XXXXXXX I XXXX SOUTĚŽ)
Všechny zakázané xxxxx x této xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxxxxx diuretika a xxxxxxxxx xxxxx, xxxxxx xxxxx optických xxxxxxx, xxxx. x- x x-, xxxx xxxxxxxx.
Xxxx xxxx xxxxxx:
•&xxxx; Diuretika, xxxx např.:
acetazolamid; xxxxxxxx; xxxxxxxxx; kanrenon; xxxxxxxxxxxx; xxxxxxxx xxxxxxxxxx; xxxxxxxxx; xxxxxxxxx; xxxxxxxxx; spironolakton; xxxxxxxx, např. bendroflumethiazid, xxxxxxxxxxxxx x xxxxxxxxxxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx;
• Vaptany, xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx;
• Plazmatické xxxxxxxxx xxxxxxxx xxxxxxxxxxxx, xxxx.:
xxxxxxx, xxxxxxx, xxxxxxxxxxx xxxxx, xxxxxxxx;
• Desmopresin;
• Probenecid;
a xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
XXXXXXX
• xxxxxxxxxxx; pamabrom; x lokální oftalmologické xxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. dorzolamid, xxxxxxxxxxx);
• xxxxxxx xxxxxx xxxxxxxxxxx x xxxxx anestezii.
POZNÁMKA
Nález xxxxxxxxxxx množství látky xx xxxxxxxxxx xxxxxxxx xxxxxxx: u xxxxxxxxxxx, xxxxxxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxxxxxx x pseudoefedrinu xx Xxxxxx Xxxxxxxxx xxxxxxxx nebo případně Xxx Xxxxxxx ve xxxxxxx x xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx (xxxxx lokálního xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxxx nebo xxxxxxxxx xxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx), xxxx xxxxxxxxx xx Pozitivní xxxxxxxxxxx xxxxx (XXX), xxxxx Sportovec nemá xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) na tuto xxxxx xxxxx x xx, xxxxx již xxxx xxxxxxx na xxxxxxxxxx xxxx xxxxx xxxxxxxxx látku.
ZAKÁZANÉ XXXXXX
XXXXXXXX XXXXX (PŘI SOUTĚŽI X XXXX XXXXXX)
Xxxxxxx xxxxxxxx metody v xxxx třídě xxxx Xxxxxxxxxxxx x výjimkou xxxxx v X2.2, xxx xxxx Specifické xxxxxx.
X1. XXXXXXXXXX X XXXX X XXXXXXXX XXXXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
X1.1. Xxxxxx xxxx opětovné xxxxxxxx jakéhokoliv xxxxxxxx xxxxxxxxx, xxxxxxxxx (homologní) xxxx heterologní krve xxxx produktů z xxxxxxxxx xxxxxxx jakéhokoliv xxxxxx xx oběhového xxxxxxx s xxxxxxxx xxxxxxxx xxxxxx xxxx xxxxxx složek Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxx provedené x registrovaném xxxxxxxxx xxxxxx.
X1.2. Umělé xxxxxxxxx xxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx.
Xxxx jiné xxxxxx:
Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (XXX13); xxxxxxxxx a xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, např. xxxxxx xxxxxxxx xx xxxx xxxxxxxxxxx x xxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, x xxxxxxxx doplňkového xxxxxxx xxxxxxxx.
X1.3. Xxxxxxxxx xxxxx intravaskulární xxxxxxxxxx x xxxx nebo x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx nebo xxxxxxxxxx xxxxxxx.
X2. CHEMICKÁ X XXXXXXXXX MANIPULACE
Zakázané xx xxxxxxxxxxx:
X2.1. Xxxxxxxxx nebo Xxxxx o podvod xx xxxxxx xxxxxxx xxxxxxxxx a xxxxxxxx Xxxxxx xxxxxxxxxx při Xxxxxxxxx xxxxxxxx.
Xxxx xxxx xxxxxx:
Xxxxxx x/xxxx úprava Xxxxxx, xxxx. xxxxxxxx xxxxxxx ke Xxxxxx.
X2.2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx více xxx xxxxxx 100 xx xx 12 hodin xxxxx xxxxxx xxxxxxxxx xxxxxxxxx v xxxxxxx xxxxxxxxxxxx xxxxxxxx, chirurgických xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxxx vyšetření.
M3. GENOVÝ X BUNĚČNÝ DOPING
Z xxxxxx potencionálního xxxxxxx xxxxxxxxxxx výkonu xx xxxxxxxx xxxxxxxxxxx:
X3.1. Xxxxxxx xxxxxxxxxx xxxxxxx nebo xxxxxx analogů, xxxxx xxxxx xxxxxx xxxxxxxx xxxxxx a/nebo xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxx. Xx mimo xxxx xxxxxxxx technologie úprav xxxx, xxxxxxxxx xxxx x xxxxxxxxxxx xxxxxxx xxxx.
X3.2. Xxxxxxx normálních xxxx geneticky modifikovaných xxxxx.
X6 XXXXXXXXXXX
XXXXXXXX XXX XXXXXXX
Xxxxxxx xxxxxxxx xxxxx x této xxxxx xxxx Xxxxxxxxxx látky x xxxxxxxx látek xxxxxxxxx x X6.X, xxx xxxx Nespecifické xxxxx.
Xxxxxxxx látky x xxxx xxxxx: xxxxxx x xxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“)
Xxxxxxx xxxxxxxxxxx, včetně xxxxx xxxxxxxxx xxxxxxx, např. x- x x-, xxxx zakázána.
Stimulancia xxxxxxxx:
X6.X: XXXXXXXXXXXX XXXXXXXXXXX
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx [4-xxxxxxxxxxxxxx (xxxxxxxx)] |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxx |
|
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxx(x-) |
|
|
• |
xxxxxxxxx |
• |
x-xxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxx |
• |
xxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxxx |
Xxxxxxxxx, xxxxx není xxxxxxxx uveden x xxxxx xxxxxx, je Xxxxxxxxxxx xxxxxx.
X6.X: XXXXXXXXXX XXXXXXXXXXX
Xxxx xxxx xxxxxx:
|
• |
2-xxxxxxxxxxx-1-xxxx (ß-xxxxxxxxxxxxxx-xxxx, XXXXX) |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
3-xxxxxxxxxx-2-xxxx (1,2-xxxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx (xxxxxxxxxxxxx) |
||
|
• |
4-xxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxx |
||
|
• |
4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 XXXX, metylhexanamin) |
• |
heptaminol |
• |
pentetrazol |
||
|
• |
4-methylpentan-2-amin (1,3-dimethylbutylamin) |
• |
hydrafinil (xxxxxxxxx) |
• |
xxxxxxxxxxx a xxxx xxxxxxxx |
||
|
• |
5-xxxxxxxxxx-2-xxxx (1,4-xxxxxxxxxxxxxxx, 1,4-dimetylpentylamin, 1,4-XXXX) |
• |
xxxxxxxxxxxxxxxx (parahydroxyamfetamin) |
• |
fenmetrazin |
||
|
• |
benzfetamin |
• |
isomethepten |
• |
fenprometamin |
||
|
• |
katin1) |
• |
levmetamfetamin |
• |
propylhexedrin |
||
|
• |
katinon x xxxx xxxxxxx, xxxx. xxxxxxxx, metedron x ɑ-xxxxxxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxxxx2) |
||
|
• |
xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxx3) |
• |
xxxxxxxxxxxx3) |
• |
xxxxxxxxxx |
||
|
• |
xxxxxxxxx (adrenalin)4) |
• |
metylnaftidát [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- xx)xxxxxx] |
• |
xxxxxxxxxxxx |
||
|
• |
xxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx (metylendioxyamfetamin) |
||
|
• |
etylamfetamin |
• |
norfenefrin |
• |
tuaminoheptan |
||
|
• |
etilefrin |
• |
oktodrin (1,5-xxxxxxxxxxxxxxxx) |
x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky
VÝJIMKY
• xxxxxxxx;
• xxxxxxxx xxxxxxxxxxx x xxxxxxx xxxxxx xxxxxxx, xxxxxxx, xxxxxx xxxx xxxxxx xxxxxxx (xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, nafazolin, oxymetazolin, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxx) x xxxxxxxxxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 20245).
X7 XXXXXXXXX
XXXXXXXX XXX XXXXXXX
Xxxxxxx zakázané xxxxx x této třídě xxxx Xxxxxxxxxx xxxxx.
Xxxxxxxx xxxxx v této xxxxx: xxxxxxxxx (xxxxxx)
Xxxxxxxxxxx xxxxxxxxx, xxxxxx jejich xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxx, např. x- x x, jsou xxxxxxxx.
|
• |
xxxxxxxxxxx |
• |
xxxxxxxx x xxxx xxxxxxxx |
• |
xxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
|||
|
• |
xxxxxxxxx (xxxxxx) |
• |
xxxxxxx |
• |
xxxxxxxx |
• |
xxxxxxxx |
|||
|
• |
xxxxxxxxx |
X8 KANABINOIDY
ZAKÁZANÉ XXX XXXXXXX
Xxxxxxx zakázané xxxxx v xxxx xxxxx jsou Xxxxxxxxxx xxxxx. Xxxxxxxx látky x této sekci: xxxxxxxxxxxxxxxxxxx (XXX)
Xxxxxxx xxxxxxxx x syntetické kanabinoidy xxxx xxxxxxxx, xxxx.
• x xxxxxx (xxxxx, xxxxxxxxx) x xxxxxxxxx xxxxxxxxxx
• přírodní a xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx (XXX)
• xxxxxxxxxx kanabinoidy xxxxxxxxxxxx xxxxxx XXX
XXXXXXX
• xxxxxxxxxx
X9 XXXXXXXXXXXXXXX
XXXXXXXX XXX XXXXXXX
Xxxxxxx xxxxxxxx látky v xxxx třídě xxxx Xxxxxxxxxx látky.
Všechny glukokortikoidy xxxx zakázány, pokud xxxx xxxxxxxx xxxxxxxxxx xxxxxxxx, xxxxxxxxx [včetně xxxxxxxxxx (xxxx. xxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx)] nebo xxxxxxxx cestou.
Mimo xxxx xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxxx xxxxxxxx |
||
|
• |
xxxxxxxx |
• |
xxxxxxxxxxxxx |
||||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxxxxx |
XXXXXXXX
• Jiné xxxxxxx xxxxxx (včetně xxxxxxxxxxx x xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, xxxxxx x xxxxxxxxxxxx) xxxxxx xxxxxxxx, xxxxx xx xxxxxxxxx x xxxxx xxxxxxxx xxxxxxxxxxxx xxxxx a xxxxxxxxxxxxxx xxxxxxxx.
X1 BETA-BLOKÁTORY
ZAKÁZANÉ X XXXXXXXX SPORTECH
Všechny xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxx xxxxx.
Xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxxxx Xxx Xxxxxxx x xxx xx to označeno xxxxxxxx (*) x Xxxx xxxxxx.
• xxxxxxxxxxx (XX)*
• xxxxxxxx/xxxxxxxxxxxx (XXX) – xxxxx xx xxxxxx, xxxxxxxxxxx xxxxx / X-xxxxx a xxxxxxxxx X-xxxxx / xxx air
• xxxxxxxxxxxx xxxxx (XXX)
• xxxxxxxx xxxxxx (CMAS)* x xxxxxxxxxxxx volného xxxxxxxx, xxxx harpunou a xxxxxxx xx xxxx
• xxxxxxxx (xxxxxxx disciplíny) (XXXX)
• šipky (WDF)
• xxxx (IGF)
• minigolf (XXX)
• střelba (XXXX, XXX)*
* zakázané také Xxxx xxxxxx
Xxxx xxxx xxxxxx:
|
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxx |
|||
|
• |
xxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxx |
Xxxxxxx č. 2
Xxxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxx jazyce
1) katin (x-xxxxxxxxxxxxxxxx) a xxxx x-xxxxxx: xx zakázaný xxxxx při koncentraci x xxxx xxxxx xxx 5 xxxxxxxxxx x 1 xx.
2) xxxxxxxxxxxxx: xxxxxxxx xxxxx xxx xxxxxxxxxxx x xxxx xxxxx než 150 xxxxxxxxxx x 1 xx.
3) xxxxxxx x xxxxxxxxxxxx: xxxxxxxx xxx xxxxxxxxxxx x xxxx xxxxx než 10 mikrogramů v 1 xx.
4) xxxxxxxxx (xxxxxxxxx): xxxx xxxxxxxx xxxxxxx xxxxxxxx, např. xxxxx, xxxx, xxxx xxxxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxx.
5) bupropion, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx a xxxxxxxx: xxxx látky xxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2024 x nejsou xxxxxxxxxx xx Xxxxxxxx xxxxx.
Xxxxxxxxx
Xxxxxx předpis č. 19/2025 Sb. nabyl xxxxxxxxx xxxx 28.1.2024.
Xxxxx xxxxxxxxxxxx právních norem xxxxxx xxxxxxxx předpisů x xxxxxxxx není xxxxxxxxxxxxx, xxxxx xx xxxx netýká xxxxxxxxx xxxxx xxxxx uvedeného xxxxxxxx předpisu